IOVA — Iovance Biotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $2.23bn
- $1.87bn
- $1.19m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 307 | 629 | 504 | 472 | 280 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | — | — | 0.151 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 316 | 636 | 508 | 479 | 308 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 19.2 | 114 | 170 | 178 | 177 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 345 | 768 | 777 | 664 | 780 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 39.1 | 54.9 | 89.2 | 91.5 | 110 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 45.7 | 112 | 156 | 164 | 196 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 299 | 656 | 622 | 500 | 585 |
Total Liabilities & Shareholders' Equity | 345 | 768 | 777 | 664 | 780 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |